Viral vectors: promising new therapeutics in the battle against glioblastoma

References

• Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4(1), 39–69 (1993).
   PubMed Web of Science ®Google Scholar
• Harsh GR, Deisboeck TS, Louis DN et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg. 92(5), 804–811 (2000).
   PubMed Web of Science ®Google Scholar
• Rainov NG. A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11(17), 2389–2401 (2000).
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1(9), 938–943 (1995).
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10(11), 983–990 (2003).
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7(10), 867–874 (2000).
   PubMed Web of Science ®Google Scholar
• Markert JM, Liechty PG, Wang W et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17(1), 199–207 (2009).
   PubMed Web of Science ®Google Scholar
• Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 12(5), 842–851 (2005).
   PubMed Web of Science ®Google Scholar
• Ostertag D, Amundson KK, Lopez Espinoza F et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-oncology 14(2), 145–159 (2012).
   PubMed Web of Science ®Google Scholar
• Wang W, Tai CK, Kershaw AD et al. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg. Focus 20(4), E25 (2006).
   PubMedGoogle Scholar
• Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl. Cancer Inst. 98(1), 38–50 (2006).
   PubMed Web of Science ®Google Scholar
• Hadjipanayis CG, Fellows-Mayle W, Deluca NA. Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol. Ther. 16(11), 1783–1788 (2008).
   PubMed Web of Science ®Google Scholar
• Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells. Bioeng. Bugs 1(6), 429–433 (2010).
   PubMedGoogle Scholar
• Stanziale SF, Petrowsky H, Joe JK et al. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132(2), 353–359 (2002).
   PubMed Web of Science ®Google Scholar
• Thaci B, Ulasov IV, Ahmed AU, Ferguson SD, Han Y, Lesniak MS. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther. doi:10.1038/gt.2012.42 (2012) (Epub ahead of print).
   Google Scholar
• Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 67(2), 440–444 (2007).
   PubMed Web of Science ®Google Scholar
• McKee TD, Grandi P, Mok W et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66(5), 2509–2513 (2006).
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res. 14(12), 3933–3941 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. 66(4), 2314–2319 (2006).
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103(34), 12873–12878 (2006).
   PubMed Web of Science ®Google Scholar